Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.

Other equities analysts have also issued reports about the company. EF Hutton Acquisition Co. I raised Hoth Therapeutics to a “strong-buy” rating in a report on Wednesday, August 21st. Benchmark reiterated a “speculative buy” rating and set a $3.00 price target on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Hoth Therapeutics Price Performance

Shares of NASDAQ:HOTH opened at $0.89 on Monday. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $1.73. The company’s 50-day moving average is $0.89 and its 200 day moving average is $0.94.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Friday, August 9th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.15. On average, analysts predict that Hoth Therapeutics will post -1.18 earnings per share for the current fiscal year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.